Key highlights
Achieved seamless Bluefield implementation
Enhanced real-time analytics and data quality
Ensured FDA-compliant processes with reduced risk
Overview
Zensar partnered with the client, a global biotech leader in vaccines and generics, to transition from SAP ECC to SAP S/4HANA using a Bluefield approach on the SAP RISE platform. Leveraging automation tools, the project ensured minimal business disruption, seamless data migration, and third-party integrations while maintaining strict FDA compliance and delivering real-time analytics for enhanced productivity.
Challenges
1
Business
SAP ECC mainstream support is ending in 2027
2.
Business
Minimizing business disruption
3
Business
Avoiding risks in processes as per FDA norms
4
Business
Change management
5
Technical
Standardization and optimization of business processes
6
Technical
Legacy system complexity
7.
Technical
Data migration and integration
Solution
1
Scope
Implementing SAP S/4HANA Cloud Private Edition (RISE with SAP)
2.
Approach
Bluefield implementation with selective data transition
3
Approach
Key features include real-time analytics, improved data quality, and streamlined processes
4
Approach
Synchronous bi-directional integration of the required third-party systems with the SAP S/4HANA system
Approach
Suggested best practices by SAP
Impact
Improved decision-making capabilities, productivity, and efficiency
Reduced business disruption
Faster implementation
Single IS Pharma (SAP S/4HANA) system-driven business process solution
Customer would be working on the latest/updated tool in the market, which recognizes FDA norms and quality processes
Zensar leveraged its tools and processes to reduce risk and increase productivity